Theriva Biologics, Inc. 8-K

What Happened

• Theriva Biologics, Inc. announced in an 8-K filed April 9, 2026 that it called its Special Meeting of Stockholders but could not convene because a quorum was not present or represented by proxy.
• The meeting’s purpose was to seek stockholder approval for issuance of up to 16,184,560 shares upon exercise of new common stock purchase warrants issued under a Warrant Inducement Agreement dated October 16, 2025.
• The company filed a definitive proxy on March 16, 2026 and said it will file and mail new proxy materials with the date and time for a rescheduled meeting.

Key Details

• Date meeting failed to convene: April 9, 2026.
• Potential shares issuable on warrant exercise: up to 16,184,560 common shares.
• Relevant agreement: Warrant Inducement Agreement dated October 16, 2025.
• Requirement: Company must use reasonable best efforts to call a stockholder meeting within 60 days after closing and, unless waived, must continue calling a new meeting every 60 days until approval is obtained or the warrants are no longer outstanding.

Why It Matters

• Approval would authorize potential issuance of 16.2M shares if warrants are exercised, which could dilute existing shareholders.
• The company’s inability to obtain a quorum delays approval and means Theriva must repeatedly call meetings (administrative burden and ongoing uncertainty) until the matter is resolved or the warrants lapse.
• There were no financial results or other corporate changes reported in this filing — the item solely addresses the failed meeting and next steps to seek stockholder approval.